All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Role of Stem Cell Transplantation Evolving in Multiple Myeloma

March 11th 2015

OncLive interviewed Ravi Vij, MD, associate professor, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine and the Siteman Cancer Center, on what the future holds for stem cell transplantation in multiple myeloma.

Targeting Gastric Cancer: Recent Advances Generate Fresh Hopes After Many Frustrations

March 11th 2015

As we enter an era of unprecedented clinical trial activity in gastric cancer, with thousands of patients enrolled or set to be enrolled in large, randomized phase III trials of novel targeted agents, we may finally be on the path to changing the course of this disease.

OncLive Welcomes MD Anderson Cancer Center to Strategic Alliance Partnership Program

March 10th 2015

OncLive today joins with The University of Texas MD Anderson Cancer Center in a partnership to increase awareness of the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.

Precision Medicine: A Promising Future for Treating Cancer

March 10th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.

Tivozanib Improves PFS Versus Bevacizumab in NRP-1 Low mCRC

March 10th 2015

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Pacritinib Shows Promise for Spleen Reduction in Myelofibrosis

March 10th 2015

Pacritinib, a JAK2/FLT3 multikinase inhibitor, significantly reduced spleen volume for patients with myeloproliferative neoplasms when compared to non-JAK2 inhibitors.

FDA Approves Dinutuximab for High-Risk Neuroblastoma

March 10th 2015

The FDA has approved dinutuximab in combination with interleukin-2, GM-CSF, and 13-cis-retinoic acid as a frontline therapy for pediatric patients with high-risk neuroblastoma.

Lung Cancer Clinical Trials Could See Boost in Enrollment

March 9th 2015

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.

New Targeted Therapy Strategies on Horizon in NSCLC

March 9th 2015

OncLive sat down with Edward Kim, MD, to learn more about the impact of recent advances in NSCLC and what the future treatment paradigm might look like.

Top Breast Cancer Research Findings for the Past Year

March 9th 2015

A new standard that recommends ovarian function suppression (OFS) therapy as a routine adjuvant treatment option for certain premenopausal women with higher risk, hormone receptor (HR)–positive breast cancer emerged as the most far-reaching medical oncology research finding in the field for 2014, according to Debu Tripathy, MD.

Balancing Act: Calculating Adjuvant Treatment Risks in Older Women With Breast Cancer

March 6th 2015

Hyman B. Muss, MD, provides expert insight on adjuvant treatment for older patients with breast cancer.

FDA Approves Zarxio as First US Biosimilar

March 6th 2015

The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.

BMS, Bavarian Nordic Forge Immunotherapy Collaboration

March 5th 2015

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

AbbVie Gains Ibrutinib Through Pharmacyclics Acquisition

March 5th 2015

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

Carey Offers Views on Evolving Chemotherapy Options-and Beyond-in TNBC

March 5th 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

NCI Director Harold Varmus Resigns

March 4th 2015

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

FDA Approves Nivolumab for Lung Cancer

March 4th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Antonarakis Discusses AR-V7 and Response to Taxanes in mCRPC

March 4th 2015

Emmanuel S. Antonarakis, MBBCh, discusses research examining AR-V7 as a biomarker for chemotherapy efficacy in advanced prostate cancer.

IU Simon Cancer Center Teams with OncLive in Strategic Alliance Partnership

March 3rd 2015

OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

Carfilzomib Doubles PFS Over Bortezomib in Phase III Multiple Myeloma Trial

March 2nd 2015

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

NEXT PAGE
PREVIOUS PAGE
x